PMID- 35408777
OWN - NLM
STAT- MEDLINE
DCOM- 20220413
LR  - 20220415
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 7
DP  - 2022 Mar 22
TI  - The Role of mTOR and eIF Signaling in Benign Endometrial Diseases.
LID - 10.3390/ijms23073416 [doi]
LID - 3416
AB  - Adenomyosis, endometriosis, endometritis, and typical endometrial hyperplasia are 
      common non-cancerous diseases of the endometrium that afflict many women with 
      life-impacting consequences. The mammalian target of the rapamycin (mTOR) pathway 
      interacts with estrogen signaling and is known to be dysregulated in endometrial 
      cancer. Based on this knowledge, we attempt to investigate the role of mTOR 
      signaling in benign endometrial diseases while focusing on how the interplay 
      between mTOR and eukaryotic translation initiation factors (eIFs) affects their 
      development. In fact, mTOR overactivity is apparent in adenomyosis, 
      endometriosis, and typical endometrial hyperplasia, where it promotes endometrial 
      cell proliferation and invasiveness. Recent data show aberrant expression of 
      various components of the mTOR pathway in both eutopic and ectopic endometrium of 
      patients with adenomyosis or endometriosis and in hyperplastic endometrium as 
      well. Moreover, studies on endometritis show that derangement of mTOR signaling 
      is linked to the establishment of endometrial dysfunction caused by chronic 
      inflammation. This review shows that inhibition of the mTOR pathway has a 
      promising therapeutic effect in benign endometrial conditions, concluding that 
      mTOR signaling dysregulation plays a critical part in their pathogenesis.
FAU - Driva, Tatiana S
AU  - Driva TS
AD  - Institute of Pathology, Neuropathology and Molecular Pathology, Medical 
      University of Innsbruck, 6020 Innsbruck, Austria.
FAU - Schatz, Christoph
AU  - Schatz C
AUID- ORCID: 0000-0001-8017-3400
AD  - Institute of Pathology, Neuropathology and Molecular Pathology, Medical 
      University of Innsbruck, 6020 Innsbruck, Austria.
FAU - Sobocan, Monika
AU  - Sobocan M
AUID- ORCID: 0000-0003-1384-9487
AD  - Division of Gynecology and Perinatology, University Medical Centre Maribor, 2000 
      Maribor, Slovenia.
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, University of 
      Maribor, 2000 Maribor, Slovenia.
AD  - Wolfson Institute of Preventative Medicine, Barts CRUK Cancer Centre, Queen Mary 
      University of London, Charterhouse Square, London EC1M 6BQ, UK.
FAU - Haybaeck, Johannes
AU  - Haybaeck J
AD  - Institute of Pathology, Neuropathology and Molecular Pathology, Medical 
      University of Innsbruck, 6020 Innsbruck, Austria.
AD  - Diagnostic and Research Center for Molecular Biomedicine, Institute of Pathology, 
      Medical University of Graz, 8010 Graz, Austria.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220322
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - *Adenomyosis/metabolism/pathology
MH  - *Endometrial Hyperplasia/pathology
MH  - *Endometriosis/pathology
MH  - *Endometritis/pathology
MH  - Endometrium/metabolism
MH  - Female
MH  - Humans
MH  - Sirolimus
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - *Uterine Diseases/pathology
PMC - PMC8998789
OTO - NOTNLM
OT  - adenomyosis
OT  - eIFs
OT  - endometriosis
OT  - endometritis
OT  - mTOR signaling
OT  - typical endometrial hyperplasia
COIS- The authors declare no conflict of interest.
EDAT- 2022/04/13 06:00
MHDA- 2022/04/14 06:00
PMCR- 2022/03/22
CRDT- 2022/04/12 01:11
PHST- 2022/02/27 00:00 [received]
PHST- 2022/03/19 00:00 [revised]
PHST- 2022/03/20 00:00 [accepted]
PHST- 2022/04/12 01:11 [entrez]
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/04/14 06:00 [medline]
PHST- 2022/03/22 00:00 [pmc-release]
AID - ijms23073416 [pii]
AID - ijms-23-03416 [pii]
AID - 10.3390/ijms23073416 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Mar 22;23(7):3416. doi: 10.3390/ijms23073416.